Millennium Management LLC Decreases Stock Holdings in Personalis, Inc. (NASDAQ:PSNL)

Millennium Management LLC decreased its stake in Personalis, Inc. (NASDAQ:PSNL - Free Report) by 45.9% in the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 1,317,296 shares of the company's stock after selling 1,118,056 shares during the period. Millennium Management LLC owned 1.86% of Personalis worth $7,614,000 at the end of the most recent quarter.

Several other hedge funds also recently modified their holdings of the stock. Lightspeed Management Company L.L.C. bought a new position in Personalis during the fourth quarter worth about $47,169,000. Jefferies Financial Group Inc. boosted its stake in shares of Personalis by 104.1% in the fourth quarter. Jefferies Financial Group Inc. now owns 39,600 shares of the company's stock valued at $229,000 after buying an additional 20,200 shares during the period. Balyasny Asset Management L.P. acquired a new position in Personalis during the fourth quarter valued at approximately $348,000. BNP Paribas Financial Markets raised its position in Personalis by 53,126.7% during the fourth quarter. BNP Paribas Financial Markets now owns 71,856 shares of the company's stock valued at $415,000 after purchasing an additional 71,721 shares in the last quarter. Finally, Ameriprise Financial Inc. raised its position in Personalis by 38.3% during the fourth quarter. Ameriprise Financial Inc. now owns 34,407 shares of the company's stock valued at $199,000 after purchasing an additional 9,535 shares in the last quarter. Institutional investors own 61.91% of the company's stock.

Analyst Ratings Changes

Several research analysts have recently issued reports on PSNL shares. Guggenheim began coverage on shares of Personalis in a report on Thursday, May 15th. They set a "buy" rating and a $6.00 price target for the company. Needham & Company LLC reaffirmed a "buy" rating and set a $7.00 price target on shares of Personalis in a research report on Thursday, April 10th. Craig Hallum began coverage on shares of Personalis in a report on Monday, March 17th. They issued a "buy" rating and a $8.00 target price on the stock. Finally, HC Wainwright increased their price objective on shares of Personalis from $8.00 to $9.00 and gave the company a "buy" rating in a research note on Wednesday, May 7th. Six investment analysts have rated the stock with a buy rating, According to MarketBeat.com, the company has an average rating of "Buy" and an average target price of $7.67.

Personalis Price Performance

NASDAQ:PSNL traded up $0.05 during trading hours on Friday, hitting $4.64. The stock had a trading volume of 463,346 shares, compared to its average volume of 1,022,031. The company has a 50 day simple moving average of $3.98 and a two-hundred day simple moving average of $4.44. Personalis, Inc. has a one year low of $1.14 and a one year high of $7.20. The firm has a market capitalization of $409.83 million, a price-to-earnings ratio of -2.76 and a beta of 1.83.

Personalis (NASDAQ:PSNL - Get Free Report) last posted its quarterly earnings data on Tuesday, May 6th. The company reported ($0.18) earnings per share for the quarter, beating the consensus estimate of ($0.23) by $0.05. The firm had revenue of $20.61 million for the quarter, compared to analysts' expectations of $17.41 million. Personalis had a negative net margin of 104.52% and a negative return on equity of 66.07%. Equities research analysts anticipate that Personalis, Inc. will post -1.4 earnings per share for the current year.

Personalis Company Profile

Personalis, Inc develops and markets advanced cancer genomic tests and analytics primarily in the United States, Europe, and the Asia-Pacific. Its tests and analytics are used by pharmaceutical companies for translational research, biomarker discovery, and development of personalized cancer therapies, as well as advanced tests are used by physicians to detect cancer recurrence, monitor cancer evolution, and uncover insights for therapy selection.